scholarly journals Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer

Oncotarget ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 86-98 ◽  
Author(s):  
Yoshimasa Miyagawa ◽  
Ayako Yanai ◽  
Takehiro Yanagawa ◽  
Junichi Inatome ◽  
Chiyomi Egawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Neutrophil To Lymphocyte Ratio ◽  
C Reactive Protein ◽  
Lymphocyte Ratio ◽  
Reactive Protein ◽  
Efficacy Of Treatment

Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer

Breast Cancer ◽  
2020 ◽  
Vol 27 (4) ◽  
pp. 732-738 ◽  
Author(s):  
Mayu Myojin ◽  
Yoshiya Horimoto ◽  
Mayuko Ito ◽  
Shigehisa Kitano ◽  
Yumiko Ishizuka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Histological Type ◽  
Neutrophil To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Clinical Responses

scholarly journals Neutrophil-to-lymphocyte ratio in metastatic breast cancer: Association with clinico-pathological features and outcome

2017 ◽  
Vol 28 ◽  
pp. v95
Author(s):  
M. Bartoletti ◽  
L. Gerratana ◽  
S. Zago ◽  
D. Basile ◽  
M.G. Vitale ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Neutrophil To Lymphocyte Ratio ◽  
Pathological Features ◽  
Lymphocyte Ratio

Urinary Neopterin, Serum Retinol, α-tocopherol and Homocysteine in Breast Cancer Patients During Treatment with Bevacizumab and Chemotherapy

Pteridines ◽  
2010 ◽  
Vol 21 (1) ◽  
pp. 87-93 ◽  
Author(s):  
Bohuslav Melichar ◽  
Hana Kalábová ◽  
Lenka Krčmová ◽  
Markéta Kašparová ◽  
Jiří Plíšek ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immune Response ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
External Beam Radiation ◽  
C Reactive Protein ◽  
Systemic Immune Response ◽  
Beam Radiation ◽  
Reactive Protein ◽  
Urinary Neopterin

Abstract Bevacizumab, monoclonal antibody targeting vascular endothelial growth factor, is effective in different tumors, including colorectal carcinoma, non-small cell lung cancer, renal cell carcinoma and breast cancer. Increased serum or urinary concentrations of neopterin, an indicator of systemic immune response, have been described in patients with tumors of different primary locations, and further increase has been observed during anticancer therapy. An increase of urinary neopterin has been described after administration of cytokines, cytotoxic chemotherapy, or external beam radiation, but less is known about the effects of targeted agents on systemic immune response. We have studied serum homocysteine, C-reactive protein, α-tocopherol and retinol, and urinary neopterin in patients with metastatic breast cancer treated with bevacizumab, taxane and carboplatin. Homocysteine and C-reactive protein were determined immunochemically. α-tocopherol, retinol and urinary neopterin were determined by high performance liquid chromatography. Homocysteine, C-reactive protein and urinary neopterin decreased, while retinol and α-tocopherol increased during the therapy. In conclusion, the treatment of patients with metastatic breast cancer with bevacizumab, taxane and carboplatin resulted in the suppression of systemic inflammatory and immune response. The suppression of systemic inflammatory and immune response was associated with an increase in serum vitamin concentrations.

Sign in / Sign up

Export Citation Format

Share Document